UCL GREAT ORMOND STREET INSTITUTE OF CHILD HEALTH

Obstetric and paediatric HIV surveillance data from the UK



July 2020 update

ISOSS is part of Public Health England's Infectious Diseases in Pregnancy Screening Programme





Integrated Screening Outcomes Surveillance Service – HIV surveillance


- Comprehensive observational surveillance of obstetric and paediatric HIV in the UK building on the long-running National Surveillance of HIV in Pregnancy and Childhood (NSHPC), in place since 1990
- Maternity reports of all pregnancies in women living with HIV through maternity units; demographics, pregnancy management, outcome
- Paediatric reports of all HIV-exposed infants and diagnosed children (<16 years) through clinics; confirmation of infection status; ongoing follow-up of diagnosed children through CHIPS
- Patient data is collected without consent by ISOSS with PHE Regulation 3 approval
- Enhanced surveillance of:
 - cases of supported breastfeeding
 - all UK-born vertical transmissions








Pregnancies in women with diagnosed HIV, 1990 to date (UK)




Source: pregnancies since 1990 reported to the ISOSS by June 2020



tegrated Screening Outcomes Surveillance Service



Maternal demographics, early 2000s and now (UK)




Median age (years)	29	34
IDU-acquired HIV	2.6%	1.0%
Perinatal HIV	0.03%	2.8%
African-born	77.2%	66.4%
Eastern Europe*-born	0.3%	6.3%

Source: pregnancies since 1990 reported through ISOSS maternity scheme by June 2020

 includes the Baltic states (Estonia, Latvia, Lithuania)

Timing of maternal HIV diagnosis, UK 1998-2019




89% of pregnancies since 2015 have been in women diagnosed preconception

* includes data from all ISOSS reporting sources; excludes 139 pregnancies missing timing of diagnosis

** reporting delay for recent years

> ISSSS Integrated Screening Outcomes Surveillance Service





Timing of diagnosis & ART at conception, UK 1998-2019

UK pregnancies (all outcomes) reported to ISOSS by June 2020

~76% of pregnancies since 2015 have been conceived on antiretroviral therapy


* contains pregnancies lacking information on precise timing of diagnosis and/or ART use

** reporting delay for recent years





Shifts in mode of delivery among diagnosed women, UK 2000-2019



UK deliveries reported to ISOSS by June 2020





12% have

Children living with HIV, UK 1986 to date 90% vertical ~2400 children* transmission living with HIV diagnosed since 1986 and reported 23 years (IQR 18-27) at end of June 2020 CHIPS Annual data on infected

* excludes 267 children with haemophilia reported through a separate scheme




children and adolescents



Transition to adult care, life-long ART and HIV



Infection status of children born to diagnosed women




UK births reported to ISOSS by June 2020





Vertical transmission in UK/Ireland, 2000-2016




Data for 2000-11 from Townsend *et al.* AIDS 2014; data for 2012-14 from Peters *et al.* CID 2016; data for 2015-16 from *Peters et al.* HIV Drug Therapy Glasgow 2018





Perinatal HIV transmission audit: UK births 2006-2013



Year of delivery (total number of cases)



Recent publications

Surveillance of Congenital Anomalies After Exposure to Raltegravir or Elvitegravir During Pregnancy in the United Kingdom and Ireland, 2008–2018

Virginia Rasi, MD, Mario Cortina-Borja, PhD, Helen Peters, MSc, Rebecca Sconza, MSc, and Claire Thorne, PhD

Pregnancy incidence and outcomes in women with perinatal HIV infection

Laura Byrne^a, Rebecca Sconza^a, Caroline Foster^b, Pat A. Tookey^a, Mario Cortina-Borja^a and Claire Thorne^a

Stillbirth in Women Living With HIV Delivering in the United Kingdom and Ireland: 2007–2015

Graziella Favarato, PhD, Claire L. Townsend, PhD, Helen Peters, MSc, Rebecca Sconza, MSc, Heather Bailey, PhD, Mario Cortina-Borja, PhD, Pat Tookey, PhD, and Claire Thorne, PhD

National audit of perinatal HIV infections in the UK, 2006–2013: what lessons can be learnt?

H Peters, C Thorne, PA Tookey and L Byrne

Protease inhibitors and preterm delivery: another piece in the puzzle

Graziella Favarato^a, Claire L. Townsend^a, Heather Bailey^a, Helen Peters^a, Pat A. Tookey^a, Graham P. Taylor^b and Claire Thorne^a



For a full list of publications, visit <u>www.ucl.ac.uk/isoss/publications</u>.


13 per 1000

woman-years

with PHIV

Pregnancies in women with perinatal HIV (PHIV)

- Of 630 women reported to ISOSS in childhood, 45 (7%) had at least one pregnancy reported
- Pregnancy incidence rate lower in PHIV than in women of similar age in general UK population pregnancy incidence rate among women
- 70 pregnancies among 45 women with PHIV were compared with 184 pregnancies among 118 age-matched women with behaviourally-acquired HIV (BHIV)



Women with PHIV were 3x more likely to have detectable viral load near delivery [OR 3.22 (CI 1.22-8.48)]

For a link to full publication, visit www.ucl.ac.uk/isoss/publications.



Maternal and pregnancy characteristics, PHIV vs. BHIV (data source: Byrne et al. 2017 AIDS)

Congenital anomalies & exposure to raltegravir or elvitegravir, 2010-2018

- No reported congenital abnormalities among 31 live-born infants exposed to EVG-based regimens
- 23 reported congenital anomalies among 886 live-born infants exposed to RAL-based regimens

Timing of first RAL exposure	N	(%)	Infants with anomaly	Prevalence of anomalies
At conception	222	(25.0%)	5	2.25% (95% CI 0.73, 5.17)
1 st trimester	40	(4.5%)	0	-
2 nd /3 rd trimester	602	(67.9%)	17	2.82% (95% CI 1.65, 4.48)
Timing unknown	22	(13.5%)	1	-
Overall	886		23	2.59% (95% CI 1.65, 3.86)

Prevalence of congenital anomalies among raltegravir-exposed infants by timing of first exposure (data source: Rasi *et al.* 2018 JAIDS)

2.59% No apparent (95% CI 1.65, 3.86) clustering of specific anomalies; overall prevalence of no reported congenital anomalies neural tube among RAL-exposed defects infants Consistent with national population estimates for time period in the UK and historic prevalence in NSHPC



Patient data are collected under legal permissions granted to PHE under Regulation 3 of The Health Service (Control of Patient Information) Regulations 2002 (see www.ucl.ac.uk/isoss/governance)

Acknowledgements

All ISOSS respondents

Public Health England's Infectious Diseases in Pregnancy Screening Programme

Contributors to the Collaborative HIV Paediatric Study (CHIPS) at the MRC Clinical Trials Unit and the clinical centres

ISOSS Team:

Surveillance Lead: Claire Thorne Surveillance Manager: Helen Peters Surveillance Coordinator: Kate Francis Surveillance Assistants: Laurette Bukasa, Rebecca Sconza Surveillance Administrator: Corinne Hill

Funding:

Public Health England NHS Infectious Diseases in Pregnancy Screening Programme





Visit the Integrated Screening Outcomes Surveillance Service (ISOSS) websites at <u>www.ucl.ac.uk/isoss</u> and <u>GOV.UK</u>